Hanmi Fine Chemical launches “high-tech CDMO” activity


Due to the COVID-19 pandemic, there has been an increase in global demand for high-level synthetic biopharmaceutical raw materials, such as those used in mRNA vaccines, including lipid nanoparticles (LNPs), nucleotides , styling materials, polyethylene glycol derivatives (PEG) and peptides. As such, on May 23, 2022Hanmi FC (CEO Chang Young-kil) announced that it will launch its business areas to include CDMO projects in relevant areas.

To this end, Hanmi FC will invest approximately 10 billion KRW build facilities for “high-tech CDMOs”. Last year, Hanmi FC was selected to lead the Korean government’s project to expand production facilities for COVID-19 vaccines and raw materials and received KRW 1.6 billion in support of such efforts. In addition, the company plans to further improve these facilities by completing 8 billion KRW on its own funds.

Hanmi Fine Chemicals has accumulated global competitiveness in CDMO field by participating in R&D for biological and anti-cancer products of Hanmi Pharmaceutical and successfully passing GMP inspections in major countries with advanced pharmaceutical sectors, such as GermanyUK, Japanand the US FDA.

In addition, Hanmi FC is currently in charge of the development and production of raw materials for Hanmi Pharmaceutical’s innovative new drugs, including Belvarafenib (in partnership with Genentech), MKI (in partnership with Aptose) and Poziotinib (in partnership with Spectrum ). It also develops and produces raw materials for TOWERSTriple agonist, TOWERSDual agonist, TOWERSglucagon analog, and TOWERSGLP-2 Analog, the core biologics of Hanmi Pharmaceutical.

Building on this competitiveness, Hanmi FC is currently carrying out preclinical and clinical CDMO projects worth 10 billion KRW with 10 domestic and foreign companies, and it is expected to partner with even more companies in the second half of 2022.

In addition, in order to expand its global business performance of CDMO, Hanmi FC actively participates in various domestic and foreign exhibitions. In May, he participated in TIDES US (9-12, Boston, UNITED STATES), ORGANIC KOREA (11-13, Seoul), and InformEx (CPhI North America, 17-19, philadelphia cream, UNITED STATES). Hanmi FC will participate in the BIO international convention, which is to be held at San Diego, UNITED STATES from June 13 to 16. Finally, at the end of this year, Hanmi FC plans to attend TIDES Europe du November 15 to 18 in Vienna, Austria.

CEO of Hanmi FC Chang Young-kil pointed out that the company enjoys sufficient global competitiveness and its ability to rapidly develop materials requiring advanced synthesis technology, such as mRNA raw materials, is already at the forefront in Korea.

[Reference Materials] About Hanmi Fine Chemical

Founded in 1984, Hanmi FC is an API company. In 1993, it built Korea’s first large-scale GMP raw material synthesis plant in Sihwa Industrial Complex, located in Gyeonggi-do.

The quality of Hanmi FC’s cephalosporin products is recognized not only in Korea, but also in developed markets such as the United States and Europe. In 2006, Hanmi FC successfully passed US FDA inspection in sterile raw material area. Besides, it has proved its global competitiveness through GMP inspection approval by leading pharmaceutical advanced countries, such as Germanythe UK and Japan. It has also secured practical capabilities for realizing global CDMOs in various fields, such as those of mass production of existing PLCs and GMP operation.

Recently, Hanmi FC has succeeded in synthesizing and developing essential raw materials for the manufacture of mRNA vaccines and plans to expand its facilities for their mass production. Excellent human resources from leading domestic and foreign pharmaceutical biological research centers, such as Hanmi Pharmaceutical Research Center, are in charge of the company’s R&D. Currently, Hanmi FC exports products to more than 30 countries around the world.

SOURCE Hanmi Pharmaceutical


Comments are closed.